Prostate Cancer International is
for 2011 by Great NonProfits
According to a news report this morning, a paper originally published in Urology (the Gold Journal) in 2007, and that reported that “early prostate cancer antigen” (EPCA) had the potential to replace the PSA test, has been retracted by the authors.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, EPCA-1, EPCA-2, risk | Leave a Comment »
We have now had the chance to look carefully through the new, patient-specific guidelines on prostate cancer issued by the National Comprehensive Cancer Network (NCCN) just before the Holidays. They are not perfect, but they are certainly a vast improvement over the NCCN’s first attempt.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, guideline, Management, NCCN, patient, risk | 16 Comments »
When Paul VanDervelder was told his PSA had spiked, he did what many men do. He panicked! But then he did what he was trained to do as an investigative journalist. He investigated.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, PSA, risk | 7 Comments »
The debate over the merits and risks of widespread screening for prostate cancer using the PSA test is hardly confined to the USA. A new article (in German) in the journal Urologie A addresses exactly the same issues as have recently received so much attention here in the States.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, mortality, PSA, risk, screening | 1 Comment »
On November 8, the American Urological Asociation (AUA) issued its full, formal comment letter on the US Preventive Services Task Force (USPSTF)’s draft recommendation of a “D” grade for the use of PSA screening in healthy men with no symptoms of prostate cancer. The AUA also issued a formal statement for the media.
Filed under: Diagnosis, Risk | Tagged: AUA, Diagnosis, PSA, risk, screening, USPSTF | 3 Comments »
An article by a highly regarded specialist in medical oncology in the most recent issue of The ASCO Post discusses recent recommendations from the U.S. Preventive Services Task Force (USPSTF).
Filed under: Diagnosis, Risk | Tagged: Diagnosis, opinion, recommendation, risk, USPSTF | 11 Comments »
A newly published paper in the Journal of Urology describes a multi-center, prospective study of the potential of the investigational, urine-based, ProCaM™ assay as a test to offer improved evaluation of the need for prostate biopsy among men with an initial total serum PSA level between 2 and 10 ng/ml.
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, epigenetic, ProCaM, PSA, risk, test | 7 Comments »
It has been noted previously in this blog that we are improving our ability to accurately identify localized prostate cancer using several types of imaging technology.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, identificantion, monitoring, MRI | 28 Comments »
Readers might want to read an article by Ralph de Vere White, MD, the Director of the UC Davis Cancer Center at the University of California Davis in Sacramento, California. Dr. de Vere White is a respected urologic oncologist known to have a strong commitment to shared decision making with patients on issues of cancer risk [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, recommendation, risk, USPSTF | 10 Comments »
The following statement about how to comment on the USPSTF recommendation that uninformed, mass screening of men for risk of prostate cancer is not supported by available evidence can be found on the USPSTF web site:
Filed under: Diagnosis, Risk | Tagged: Diagnosis, risk | 2 Comments »
The U.S. Preventive Services Task Force (USPSTF) — after previously stating that it would be releasing its new recommendations about PSA testing for risk of prostate cancer on Tuesday next week — has been pressured (by a variety of organizations, and by the media) to release its draft recommendation today.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, PSA, risk, testing, USPSTF | 14 Comments »
According to an article in today’s New York Times, the United States Preventive Services Task Force (USPSTF) has chosen to advise against routine use of the PSA test to screen healthy men for prostate cancer because “the test does not save lives and often leads to more tests and treatments that needlessly cause pain, impotence [...]
Filed under: Diagnosis, Risk | Tagged: Diagnosis, risk, screening | 10 Comments »
A population-based analysis of mortality data for men diagnosed with prostate cancer from three European nations suggests that “a small but important group of older patients” initially present with late stage prostate cancer and die rapidly as a consequence.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: Diagnosis, elderly, mortality, stage, survival | 11 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site